SR 1664

Discontinued Product

SR 1664 (Cat. No. 4409) has been withdrawn from sale for commercial reasons.
Description: High affinity PPARγ ligand; blocks Cdk5-dependent PPARγ phosphorylation
Chemical Name: 4'-[[2,3-Dimethyl-5-[[[(1S)-1-(4-nitrophenyl)ethyl]amino]carbonyl]-1H-indol-1-yl]methyl]-[1,1'-biphenyl]-2-carboxylic acid
Purity: ≥97% (HPLC)
Datasheet
Citations
Reviews
Literature (4)

Biological Activity for SR 1664

SR 1664 is an antidiabetic agent; binds to PPARγ and potently inhibits Cdk5-mediated PPARγ phosphorylation (IC50 = 80 nM; Ki = 28.67 nM) without exhibiting PPARγ agonist activity. Does not inhibit Cdk5-dependent phosphorylation of Rb. Reduces fasting insulin levels and improves insulin sensitivity in a mouse model of diabetes.

Technical Data for SR 1664

M. Wt 547.6
Formula C33H29N3O5
Storage Store at -20°C
Purity ≥97% (HPLC)
CAS Number 1338259-05-4
PubChem ID 53239854
InChI Key IIJDFXNUWZTHIM-NRFANRHFSA-N
Smiles CC2=C(C)N(CC3=CC=C(C4=CC=CC=C4C(O)=O)C=C3)C1=CC=C(C(N[C@H](C5=CC=C([N+]([O-])=O)C=C5)C)=O)C=C12

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for SR 1664

Certificate of Analysis / Product Datasheet
Select another batch:

References for SR 1664

References are publications that support the biological activity of the product.

Norris and Sigmund (2012) A second chance for a PPARγ targeted therapy? Circ.Res. 110 8 PMID: 22223206

Choi et al (2011) Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 477 477 PMID: 21892191

View Related Products by Target

Keywords: SR 1664, SR 1664 supplier, SR1664, antidiabetics, diabetes, PPARgamma, PPARg, peroxisome, proliferator, activated, receptor, ligand, Cdk5, phosphorylation, LBD, Receptors, 4409, Tocris Bioscience

Citations for SR 1664

Citations are publications that use Tocris products.

Currently there are no citations for SR 1664.

Reviews for SR 1664

There are currently no reviews for this product. Be the first to review SR 1664 and earn rewards!

Have you used SR 1664?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer Research Product Guide

Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis
Cardiovascular Research Product Guide

Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure
Nuclear Receptors Product Listing

Nuclear Receptors Product Listing

A collection of over 150 products for key nuclear receptors, the listing includes research tools for the study of:

  • Androgen Receptors
  • Estrogen Receptors
  • Retinoic Acid Receptors
  • Retinoid X Receptors
  • Vitamin D Receptors
Epilepsy Poster

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.